The Menopause Digest 10/26–11/01

Onikepe Adegbola MD PhD

20 min read

·

9 hours ago

--

Listen

Share

I curate and cut through the noise in evidence based menopause and midlife women’s health podcasts so you don’t have to

Welcome to The Menopause Digest.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) — helps preserve lean muscle during weight loss
• FODMAP Digestive Enzymes — improves absorption and reduces GI side effects
• Advanced Probiotic + Prebiotic Synbiotic Formula — supports a balanced gut microbiome
• Essential Vitamin & Mineral Complex — replenishes nutrients often depleted during rapid weight loss
• Gentle Colon Cleanse + Probiotic Support — aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested, the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin, especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex — firms and smooths for youthful elasticity
• Antioxidant C+E Ferulic Radiance Serum — brightens and defends against oxidative stress
• Needle-Free Wrinkle Smoother — softens fine lines without irritation
• Ultra Retinol 10x + Bakuchiol Serum — boosts cell turnover with gentle plant retinol
• Advanced Retinol Eye Repair — targets puffiness and under-eye wrinkles
• Cellular Repair Growth Factor Peptides Serum — rejuvenates and supports skin repair
• Advanced Neck Lift Firming Complex — improves tone and texture along the jawline and neck
• Even Tone Brightening Cream — evens discoloration for radiant, balanced skin

Dr Onyx Adegbola MD PhD — Track Smarter. Eat Better. Thrive. Download the GLP1 Support App at https://casadesante.com/pages/app-glp-1-support-by-dr-onyx-md-phd

Dr Onyx MD PhD’s Insights on this week’s episodes

Personalize the care pathway, not just the prescription

Better menopause care starts with a better visit, not a bigger prescription. This week’s strongest clinical thread connects cultural context, access and ongoing treatment adjustment.

In Menopause Matters, Let’s Talk, “Marginalised communities” shows why standard protocols need flexible delivery. Faith practices, language, disability, financial constraints and trusted community networks can determine whether treatment is usable. Asking about fasting or who participates in health decisions is not an optional courtesy. It can change medication timing, route, counseling and follow-up.

Dr. Amna Dermish reinforces that systems perspective in Hello Menopause!’s “Dr. Amna Dermish: Planned Parenthood & Menopause Care.” Comprehensive care must include contraception, mental health and continuity, not simply access to hormones. Perimenopause does not establish infertility, and menopausal hormone therapy does not provide contraception.

The prescribing counterpart appears in Health By Heather Hirsch’s “Ask Me Anything” episode on estrogen, bleeding and night sweats: adjust treatment around symptoms and tolerability rather than chasing a serum estradiol target. That principle is useful; the episode’s more individualized dosing strategies reflect clinical practice rather than cited controlled trials.

Personalization still needs guardrails. Persistent bleeding requires assessment, systemic estrogen requires appropriate endometrial protection when a uterus is present, and unresolved night sweats should prompt consideration of other causes rather than automatic dose escalation.

The strategic implication: build a repeatable visit framework with room for individual circumstances. Standardize the safety checks and follow-up, not the patient.

Treat metabolic change as a long-term risk signal, not a failure of discipline

Midlife weight gain deserves clinical assessment, not another instruction to try harder. The useful shift across this week’s metabolic episodes is from isolated symptoms to lifelong risk management.

In Hit Play Not Pause, “‘I Run, I Lift, and I’ve Gained 10 Pounds’: The Midlife Metabolism Shift,” Michelle Gordon describes how menopause-related changes in body composition, activity and fuel use can undermine an established routine. The practical message is stronger than any single numerical estimate discussed: assess cardiometabolic risk while protecting muscle through resistance training and adequate nutrition. Menopausal hormone therapy may support symptom management and body composition, but it is not a weight-loss treatment.

A GLP-1 Guide to Metabolic Health: The Plus SideZ Podcast extends the maintenance question in “GLP-1 Weight Regain: The Brain Science Behind Why It Happens.” Its emphasis on adaptive biology helps explain why weight management is not simply a willpower contest. However, the detailed leptin and dopamine narrative should be read as mechanistic interpretation, not a proven explanation for every plateau, regain episode or mood change.

For clinicians, that means planning beyond appetite suppression: monitor nutritional adequacy, strength, tolerability and mood, and discuss the possibility of long-term treatment when prescribing GLP-1–based therapy.

Dr. Barbie Taylor’s Menopause Management episode, “PMOS Management Mistakes,” adds the lifespan perspective. PCOS-related reproductive, androgenic and metabolic concerns should not disappear from the chart after fertility treatment or menopause. But comprehensive care does not mean identical treatment for everyone. The episode’s broad recommendations for combined contraception, antiandrogens and definitive surgery should not be treated as universal PCOS management.

The common priority is durable risk reduction: blood pressure, lipids, glycemic assessment, muscle preservation and treatment selected for the individual’s indications and goals.

Keep the systems thinking. Raise the evidence threshold.

Looking beyond hormones can improve care. Assuming every symptom requires specialized testing can make it more expensive without making it better. This distinction matters as menopause conversations expand into gut health, thyroid conversion and “detox.”

The contrast is clearest between The DUTCH Podcast’s “From Acne to Anti-Aging: How Birth Control, Hormones & Gut Health Are Linked” and The Skin Real’s “Hormonal acne in menopause: why your breakouts came back after 40.” The former proposes stool testing and urinary hormone-metabolite assessment; the latter offers a more immediately actionable treatment ladder built around barrier-conscious topical care and selective antiandrogen therapy.

The supplied DUTCH discussion relies substantially on clinical experience and does not establish that its testing-first approach improves acne outcomes. Skin symptoms alone do not establish gut dysfunction or a clinically harmful estrogen-metabolism pattern. Nor does the available discussion support starting menopausal hormone therapy solely for acne.

A similar filter applies to Menopause Mastery’s “Thyroid Health, Menopause & the Symptoms That Get Missed.” Persistent fatigue, weight change and cognitive symptoms deserve investigation. But the episode’s advocacy for expanded thyroid testing, ultrasound and selected T3 treatment rests largely on clinician experience rather than controlled evidence presented in the summary. Persistent symptoms justify a broader differential diagnosis, not an automatic assumption of impaired thyroid conversion.

Finally, David Mara’s “Detox Demystified” discussion on Not Your Mother’s Menopause connects genuine detoxification biology with preliminary sulforaphane and microplastic-clearance claims. A plausible cellular mechanism is not proof of meaningful human benefit. The summary supplies no controlled human outcome evidence establishing microplastic removal or menopause benefit from that approach. Avoiding unnecessary plastic contact with hot food is a reasonable precaution; promising systemic “cleanup” goes further than the evidence presented.

The emerging opportunity is whole-person care. The corresponding responsibility is to distinguish established treatment, useful clinical judgment and hypotheses that still need testing.

This week’s episodes

1. Menopause Matters, Let’s Talk

Marginalised communities

Published: 2026–10–26 | Listen

Summary

This episode emphasizes tailoring menopause care for marginalized communities through culturally sensitive communication, community partnership, and inclusive research. It offers practical pearls on managing HRT during Ramadan and key safety points for women with epilepsy, while highlighting the role of trusted networks and careful use of social media and AI in education.

Key Takeaways

• Menopause care for marginalized communities must be culturally nuanced and not treated as a monolith; include ethnic minorities, LGBTQ+ people, those with disabilities, non–English speakers, people living in poverty, those in prison, and traveler communities.
• Trust and community are central: use word-of-mouth, community leaders, and short multilingual content; involve men in discussions and avoid siloed, ‘othering’ communication.
• Historical exclusion from research and justified mistrust require investment in inclusive, community-led studies and sustained trust-building to achieve equitable evidence and care.
• For Muslim patients observing Ramadan, transdermal HRT does not break the fast; oral progesterone (e.g., Utrogestan) timing can be adapted (evening, with food as discussed) or use an LNG-IUS for progestogen; oral estrogen timing is flexible; exemptions exist for health/mental health, and prayer/community connection can alleviate symptoms.
• Epilepsy considerations: catamenial epilepsy may worsen in perimenopause and menopause may occur 3–5 years earlier; HRT can be used with low-dose estrogen and careful monitoring, particularly for interactions with lamotrigine.

Clinical Insight

Equitable menopause care begins with culturally competent history-taking — ask about faith practices (e.g., fasting), language, social roles, and community dynamics — then adapt management (e.g., HRT route/timing, nonpharmacologic supports) and monitoring (e.g., in epilepsy) accordingly.

Actionable Takeaway

At your next menopause visit, explicitly ask about cultural/faith practices (including fasting), preferred language, and who helps make health decisions, then offer transdermal HRT during fasting, review progesterone timing or consider an LNG-IUS, and if epilepsy is present, start low-dose estrogen and monitor seizure control and lamotrigine levels/response.

2. Menopause Management — Dr. Barbie Taylor

PMOS Management Mistakes (YouTube Video #460)

Published: 2026–10–26 | Listen

Summary

This episode outlines frequent management errors in PMOS/PCOS and reframes the condition as a lifelong, multisystem disorder requiring integrated dermatologic, reproductive, and metabolic care. It emphasizes early, continuous combined hormonal contraception plus antiandrogen therapy and proactive metabolic management, with attention to pregnancy complications and perimenopausal/postmenopausal risks.

Key Takeaways

• PMOS (polyendocrine metabolic ovarian syndrome; formerly PCOS) is a lifelong, multisystem disorder affecting dermatologic, reproductive, and metabolic systems; it must be managed as global, permanent, and deep rather than local, temporary, and superficial.
• Common mistakes include treating hirsutism/acne with local therapies instead of antiandrogens; ignoring irregular or absent menses or using progestogen-only regimens; and pursuing infertility treatment without addressing the underlying PMOS.
• Early and continuous combined estrogen–progestin (monophasic, continuous) contraception plus antiandrogen therapy is emphasized to control ovulatory dysfunction and androgen excess during reproductive years (unless attempting pregnancy).
• Metabolic abnormalities begin early; failing to initiate insulin sensitizers, statins when indicated, weight loss, diet, and exercise leads to serious long-term consequences akin to type 2 diabetes.
• Across perimenopause and postmenopause, the episode stresses recognizing PMOS-related risks (e.g., heavy bleeding, cancer risk, gestational diabetes/hypertension) and considering definitive gynecologic surgery (total hysterectomy with bilateral salpingo-oophorectomy) along with ongoing metabolic management.

Clinical Insight

Treat PMOS/PCOS as a chronic, multisystem endocrine–metabolic condition across the lifespan; comprehensive care should simultaneously address androgen excess, ovulatory dysfunction with combined estrogen–progestin therapy, and early, aggressive metabolic risk management rather than focusing on isolated symptoms or short-term fixes.

Actionable Takeaway

For a reproductive-age patient with PMOS/PCOS, implement a comprehensive plan: initiate a monophasic continuous combined oral contraceptive (if no contraindications), add an antiandrogen for hirsutism after ensuring reliable contraception, and begin metabolic risk management with A1c/fasting glucose or OGTT, fasting lipid panel, blood pressure and anthropometrics, lifestyle counseling (diet/exercise, weight loss if indicated), and consider metformin and statin based on results.

3. Not Your Mother’s Menopause with Dr. Fiona Lovely | Perimenopause and Menopause Support

Ep. 242 — Detox Demystified: everything you need to know to support your body’s disposal system with David Mara

Published: 2026–10–27 | Listen

Summary

This episode demystifies “detox” by explaining the liver’s three-phase system and highlighting sulforaphane’s broad activity (NRF2 activation, Phase 2 upregulation, potential benefits for estrogen metabolism, neuroinflammation/BDNF, and inflammation). It also addresses the health relevance of pervasive microplastics, offering realistic exposure-reduction strategies and discussing preliminary findings that sulforaphane may help mobilize microplastics for excretion. The discussion is most relevant to peri- and postmenopausal care, where toxin burden and estrogen metabolism are key considerations.

Key Takeaways

• Detoxification is a real, multi-step physiologic process (Phase 1: chemical modification; Phase 2: conjugation; Phase 3: binding/excretion). Sulforaphane (from broccoli sprouts) uniquely supports all three phases — dampening Phase 1 and accelerating Phase 2 — potentially avoiding the “detox flu” triggered by Phase 1–only stimulators.
• Most “broccoli” supplements contain the stable precursor glucoraphanin (plus or minus myrosinase) rather than active sulforaphane; stabilized sulforaphane is rare. Two capsules of the guest’s product (~10 mg sulforaphane) were described as equivalent to ~5 lbs of mature broccoli by their extraction method.
• Compared with DIM (a downstream metabolite from indole-3-carbinol) that largely influences Phase 1, sulforaphane may more comprehensively support estrogen metabolism across detox phases — relevant for peri/menopausal patients and those considering HRT.
• Microplastics are ubiquitous (air, water, food), act as ‘Trojan horses’ carrying BPA, phthalates, and heavy metals, and can accumulate in lysosomes. The guest cited preliminary data that sulforaphane can mobilize microplastics for fecal excretion; resveratrol may augment clearance pathways.
• Practical exposure reduction steps include: using a HEPA air purifier in the bedroom (major source is indoor air), reverse-osmosis drinking water, avoiding heating food/drink in plastic (microwave containers, plastic-lined paper cups, nylon tea bags, coffee pods), and favoring glass/stainless steel; textiles (nylon/polyester/spandex) shed microplastic fibers.

Clinical Insight

For midlife women, supporting endogenous detoxification — particularly by enhancing Phase 2 conjugation and overall NRF2-driven cytoprotective pathways with sulforaphane — may help process reactive estrogen metabolites and environmental toxicants (including microplastics) more safely, while avoiding Phase 1–dominant ‘detox’ approaches that can worsen symptoms.

Actionable Takeaway

Advise patients to stop heating food or beverages in plastic (e.g., microwave containers, plastic-lined paper cups/lids, nylon tea bags, single-serve coffee pods) and switch to glass or stainless steel for storage and reheating to meaningfully reduce daily microplastic exposure.

4. The DUTCH Podcast

From Acne to Anti-Aging: How Birth Control, Hormones & Gut Health Are Linked

Published: 2026–10–27 | Listen

Summary

This episode explores the gut–skin–hormone axis and outlines a functional, stepwise approach — stool testing, urinary hormone metabolites, and stress/lifestyle interventions — to address acne and skin aging from the inside out. It underscores the importance of hormone metabolism (not just levels), potential androgenic effects of certain contraceptives, and personalized sequencing of care, with external procedures used as adjuncts. Note: Many points reflect clinical experience; specific studies were not cited for several claims.

Key Takeaways

• Skin health tightly reflects gut and hormone status: dysbiosis, leaky gut, and stress-driven autonomic imbalance can manifest as acne, rosacea/eczema, and accelerated aging (“digest-aging”).
• A 360° evaluation is emphasized: stool testing (e.g., Genova GI Effects), blood work, and urinary hormone metabolite testing (e.g., DUTCH Complete with OAT markers) to individualize treatment.
• Hormone metabolism matters as much as levels: unfavorable estrogen pathways (e.g., higher 16‑OH vs 2‑OH, poor methylation) and androgenic influences (including levonorgestrel IUDs) can drive sebaceous activity and acne; “clear the drain” before adding hormones.
• Therapeutic sequencing uses a clear–correct–protect framework: reduce overgrowths, replete deficiencies (notably vitamin D and B vitamins with OCP use), and protect the mucosa (e.g., glutamine; support butyrate) alongside stress regulation and mindful, seated meals.
• Procedural and topical supports (PRP/microneedling-like tech, radiofrequency, exosomes/PDRN, peptides like GHK‑Cu, targeted skincare) complement inside-out care; GLP‑1s may help select patients but dosing should be conservative to avoid motility issues.

Clinical Insight

For women presenting with ‘hormonal’ skin concerns, prioritize assessment of gut integrity and hormone metabolism (urinary metabolites) rather than relying on serum levels or topical/symptom-only therapies; correcting dysbiosis and metabolic pathways often resolves dermatologic symptoms without escalating hormone doses.

Actionable Takeaway

Before initiating or increasing hormone therapy or antiandrogens for adult female acne, order a urinary hormone metabolite panel (e.g., DUTCH Complete) to evaluate estrogen and androgen pathways and use the results to guide diet (e.g., cruciferous vegetables) and targeted interventions.

5. A GLP-1 Guide to Metabolic Health: The Plus SideZ Podcast

GLP-1 Weight Regain: The Brain Science Behind Why It Happens

Published: 2026–10–27 | Listen

Summary

This episode explains why weight regain can occur even while taking GLP‑1 medications, emphasizing the brain’s adaptive defenses and the central role of leptin resistance in chronic obesity. The guest outlines how GLP‑1s temper reward‑driven food seeking yet work best when paired with a structured, whole‑food diet and habit‑based automaticity, while clinicians monitor for anhedonia and addictive eating. Relevance: Integrating brain‑based counseling and nutrition/behavior frameworks with pharmacotherapy can improve long‑term outcomes.

Key Takeaways

• Weight regain on GLP‑1 therapy is common over time; the brain defends body weight via adaptive changes (e.g., lower thyroid output, higher ghrelin, reduced NEAT, altered satiety hormones), making long‑term maintenance difficult.
• Leptin — not GLP‑1 or GIP — is the primary body‑weight regulation hormone; in obesity, leptin resistance (driven by hyperinsulinemia, high triglycerides, and inflammation) prevents the brain from ‘seeing’ leptin, perpetuating insatiable drive to eat calorie‑dense foods.
• GLP‑1s reduce appetite and ‘food noise’ partly by blunting dopamine spikes in the mesolimbic reward pathway; in individuals with baseline dopamine downregulation, this can unmask or worsen anhedonia and low motivation.
• Medication alone is rarely sufficient: pairing GLP‑1s with a structured, automatizable whole‑food dietary pattern (e.g., minimizing sugar/flour/ultra‑processed foods) and behavioral guardrails improves durability and helps restore metabolic markers linked to leptin sensitivity.
• Building automaticity (habit scripts) around meals — rather than relying on constant willpower or complex counting — reduces decision fatigue and supports long‑term adherence; community support and movement add beneficial neurochemical reinforcement.

Clinical Insight

Set clear expectations that GLP‑1s are effective but must be combined with structured, whole‑food nutrition and behavior design to counteract the brain’s weight‑defense mechanisms; screen for addictive eating patterns and anhedonia during follow‑up, and address leptin resistance indirectly by improving metabolic health (lower insulin, triglycerides, and inflammation).

Actionable Takeaway

Co‑create a repeatable 1‑week meal routine patients can automate: each meal = protein + high‑fiber vegetables + whole‑grain/starch + fruit; advise minimizing sugar, flour, and ultra‑processed foods; schedule a 4–6‑week follow‑up to reassess weight trend, hunger/‘food noise,’ and mood (e.g., brief anhedonia screen such as SHAPS) and adjust GLP‑1 dosing or supports as needed.

6. Hello Menopause!

Dr. Amna Dermish: Planned Parenthood & Menopause Care

Published: 2026–10–28 | Listen

Summary

This episode highlights Planned Parenthood’s role in delivering comprehensive, equitable menopause care and the need for individualized, longitudinal management rather than one-size-fits-all solutions. It underscores systemic barriers (including medication shortages and bias), the importance of contraception counseling in perimenopause, and the clinician’s role in guiding patients through misinformation toward credible resources.

Key Takeaways

• Planned Parenthood has long provided menopause care and is proactively expanding awareness that it offers comprehensive, accessible, patient-centered services across the entire reproductive lifespan, including perimenopause and beyond.
• High-quality menopause care must be individualized: assess physical and emotional symptoms, medical history, and goals; consider hormone therapy when appropriate, offer nonhormonal options when needed, coordinate mental health and specialty referrals, and ensure timely follow-up rather than one-time prescribing.
• Systemic issues — especially the longstanding devaluation of women’s health — contribute to gaps in care, medication shortages (e.g., estrogen patches), and disparities; Black women tend to experience earlier, more severe, and longer-lasting symptoms and are more likely to be dismissed by clinicians.
• Perimenopause does not equal infertility; unintended pregnancy risk persists at the edges of the reproductive lifespan, making contraception counseling an essential part of perimenopause care.
• Patients face an information glut and commercial “quick-fix” offerings (including online HRT and GLP‑1s); clinicians should help patients vet sources, be cautious with compounded or poorly vetted products, screen for contraindications (e.g., eating disorders), and direct patients to credible resources (e.g., menopause.org, Planned Parenthood).

Clinical Insight

Do not assume infertility in perimenopause — routinely address pregnancy risk and contraception while delivering individualized symptom management (hormonal or nonhormonal) with structured follow-up.

Actionable Takeaway

Implement a standardized perimenopause visit workflow that includes a symptom inventory (vasomotor, mood, sleep, sexual health), medical history/contraindication review, explicit contraception counseling, discussion of evidence-based options (HRT and nonhormonal), credible patient resources, and a follow-up appointment in 8–12 weeks to reassess and adjust therapy.

7. Hit Play Not Pause

“I Run, I Lift, and I’ve Gained 10 Pounds”: The Midlife Metabolism Shift with Michelle Gordon, DO (Episode 298)

Published: 2026–10–28 | Listen

Summary

This episode explores why many active midlife women gain weight — especially visceral fat — despite unchanged training and diet, highlighting menopause-related declines in fat oxidation, reduced NEAT, and early insulin resistance. The discussion covers the supportive role of MHT, the central importance of resistance training and adequate protein, and a nuanced look at GLP-1 therapies, including benefits, side effects, and long-term considerations for athletes. Some data points were discussed verbally and may be evolving; clinicians should verify details in the primary literature.

Key Takeaways

• During the menopause transition, resting and exercise fat oxidation declines (~30%), non-exercise activity (NEAT) drops, and energy balance shifts — so active women can gain visceral fat and weight despite “doing everything the same.”
• Visceral adiposity is inflammatory and metabolically harmful (e.g., raises LDL via portal circulation); menopausal hormone therapy (MHT) can help reduce visceral fat and improve symptoms but is not a weight-loss treatment.
• Insulin resistance often rises early in perimenopause; fasting insulin increases before A1c and can be a useful early marker to check in women with unexplained weight gain and central adiposity.
• GLP-1–based therapies do more than suppress appetite: they act centrally on satiety and peripherally on glucose/insulin dynamics and show cardiovascular benefits; however, many patients require long-term therapy and should pair treatment with resistance training and adequate protein to preserve lean mass.
• In athletes using GLP-1s, motivation and fueling can be challenging; periodizing training and carefully adjusting dose may help, while prioritizing lifting (at least ~20 minutes twice weekly) and protein protects muscle and bone.

Clinical Insight

In perimenopause, a physiologic decline in fat oxidation and NEAT, coupled with rising fasting insulin, drives visceral fat gain and metabolic risk even in highly active women; addressing this requires a metabolic approach — MHT when indicated, targeted resistance/HIIT, early detection of insulin resistance, and selective use of anti-obesity medications (e.g., GLP-1s) rather than “calories in–calories out” alone.

Actionable Takeaway

For midlife women with new central weight gain despite stable training and diet, add fasting insulin to labs (along with A1c and lipids) and counsel immediate initiation of twice-weekly resistance training plus adequate protein; consider MHT for symptomatic women and discuss GLP-1 therapy when metabolic risk and/or visceral adiposity remain elevated.

8. Menopause Mastery

Thyroid Health, Menopause & the Symptoms That Get Missed

Published: 2026–10–28 | Listen

Summary

Functional medicine endocrinologist Dr. Sadia Mian highlights commonly missed aspects of thyroid care in perimenopause/menopause, emphasizing free T3, the effects of stress and nutrients on T4-to-T3 conversion, and the added value of thyroid ultrasound when labs are inconclusive. She also reviews individualized, safety-focused use of BHRT within a whole-person framework that addresses lifestyle and metabolic health. Adopting this systems approach can reduce misdiagnosis and improve quality of life for symptomatic midlife women.

Key Takeaways

• Normal TSH and free T4 can mask clinically relevant low free T3; impaired T4-to-T3 conversion is often driven by stress/cortisol, nutrient deficits (selenium, zinc, iron, iodine), and gut dysfunction.
• Thyroid care should be whole-person: chasing labs with escalating thyroid meds alone often fails if adrenal stress, receptor sensitivity, or metabolic issues are unaddressed; thyroid medication can also accelerate cortisol metabolism.
• Point-of-care thyroid ultrasound adds diagnostic value beyond labs — revealing inflammation compatible with Hashimoto’s, gland atrophy after long-standing disease, or nodules (≈95% benign) that are common in women and sometimes more frequent with insulin resistance/PCOS (clinical observation).
• Many patients feel better when T3 is thoughtfully added to T4 therapy with careful titration; the thyroid is an area where the art of medicine matters and guidelines that focus only on TSH/T4 may miss symptomatic patients.
• BHRT can be safe and effective when individualized by trained clinicians with attention to contraindications and foundational lifestyle (sleep, nutrition, exercise, insulin resistance); menopause symptoms warrant evaluation beyond “eat less, move more,” and women have agency in choosing care.

Clinical Insight

In midlife women with fatigue, weight gain, or cognitive slowing despite a “normal” TSH/free T4, low free T3 from impaired conversion is common and frequently missed; combining a fuller thyroid panel with root-cause evaluation (stress, nutrients, gut) and targeted use of thyroid ultrasound improves diagnostic yield and symptom outcomes.

Actionable Takeaway

Include free T3 in thyroid testing, and when symptoms persist despite normal TSH/free T4, assess conversion factors (iron/ferritin, selenium, zinc, iodine; cortisol/stress; gut health) and consider ordering a thyroid ultrasound to evaluate for Hashimoto’s-like changes, atrophy, or nodules.

9. Health By Heather Hirsch

Ask Me Anything: Answering YOUR Questions About Estrogen, Managing Bleeding, Night Sweats & More!

Published: 2026–10–30 | Listen

Summary

This AMA episode covers practical, nuanced MHT management: dosing by symptoms rather than labs; stepwise estrogen titration; timing/route adjustments (including BID gel use) to target specific symptom patterns; and strategic options like Duavee or an IUD for bleeding. It also highlights evaluating alternative causes of refractory night sweats and acknowledges that a subset of women may need higher-than-labeled estrogen doses under careful supervision. No specific clinical trials were cited; guidance reflects expert clinical practice and drug-label–based knowledge.

Key Takeaways

• Individualize menopausal hormone therapy (MHT) based on patient-reported symptoms and side effects rather than chasing serum estradiol levels; aim for ~70–80% symptom improvement and adjust accordingly.
• Ultra–low-dose estradiol options (e.g., Menostar 0.014 mg/week) can provide bone-protective benefits for women without significant vasomotor symptoms or for those seeking bone support; consider restarting within 10 years of menopause/onset or within 10 years off HRT.
• Titrate estrogen stepwise (e.g., 0.05 → 0.075 → 0.1 patch) and use formulation timing to target symptoms (e.g., add evening gel/spray for nocturnal sweats); signs of excessive estrogen include breast tenderness, bleeding, migraines, and mood changes.
• Splitting topical estradiol doses (e.g., Divigel BID) can smooth levels in fast metabolizers; collaborate with clinicians to align packet strengths to the split regimen once stability is confirmed.
• Duavee (conjugated estrogens/bazedoxifene) is a useful option in peri/postmenopause, especially for progesterone intolerance, persistent bleeding on standard MHT, or higher breast risk profiles; consider IUD (e.g., levonorgestrel) as another strategy for HRT-associated bleeding control. Persistent vasomotor symptoms warrant considering non-menopausal causes (e.g., glucose dysregulation, thyroid disease, sleep apnea).

Clinical Insight

The most clinically impactful point is to prioritize symptom-guided, patient-centered titration of MHT — rather than targeting specific estradiol lab values — while flexibly adjusting dose, route, and timing to reach each patient’s therapeutic “sweet spot.”

Actionable Takeaway

When a patient on MHT develops new breast tenderness, down-titrate the estrogen one step (e.g., from a 0.05 to a 0.0375 patch) and reassess in 2–4 weeks before ordering labs; if tenderness persists, evaluate the progesterone contribution by holding or adjusting it briefly as clinically appropriate.

10. The Skin Real ®

Hormonal acne in menopause: why your breakouts came back after 40

Published: 2026–10–31 | Listen

Summary

This episode explains why acne often reappears after 40, highlighting estrogen’s protective role and how its decline creates a relative androgen excess that triggers midlife breakouts. It outlines a practical, tolerability-focused treatment ladder — topicals first with barrier support, selective add-ons, short-course antibiotics only as a bridge, consideration of spironolactone, and procedural options — while noting the current lack of evidence to use menopausal hormone therapy solely for acne.

Key Takeaways

• Estrogen fluctuations in perimenopause and a sustained decline post-menopause reduce estrogen’s protective effect on skin, creating relative androgen dominance that drives adult-onset acne; concurrent barrier fragility increases dryness, irritation, and sensitivity.
• Hormonal acne in midlife commonly involves the lower face/jawline; approximately 25% of women in their 40s and 15% in their 50s are affected, with stress, lifestyle factors, and some medications potentially exacerbating flares.
• First-line therapy remains topical: prioritize tolerable retinoids (e.g., adapalene or low-strength tretinoin), support the barrier with non-comedogenic moisturizers, and consider adjuncts such as azelaic acid, benzoyl peroxide washes for inflamed lesions, limited salicylic acid use, and topical antibiotics during flares; topical clascoterone can be a useful antiandrogen add-on.
• Systemic options include short courses of oral antibiotics only as a bridge, spironolactone as an effective, well-tolerated antiandrogen for midlife women (also helping hirsutism and hair thinning), and isotretinoin reserved as a last-line due to dryness and relapse risk when androgen drivers persist.
• In-office interventions include intralesional corticosteroid injections for nodulocystic lesions and emerging 1726-nm lasers that target sebaceous glands (cash-pay, multi-session); while menopausal hormone therapy may theoretically help, evidence for acne improvement is lacking and HRT is not recommended solely for skin concerns.

Clinical Insight

In midlife female patients, perimenopausal/menopausal estrogen decline leads to relative androgen dominance and barrier fragility; effective care prioritizes gentler, barrier-supportive topical regimens and early consideration of antiandrogen strategies (e.g., spironolactone, topical clascoterone) over prolonged antibiotics or defaulting to isotretinoin.

Actionable Takeaway

For a perimenopausal woman with lower-face acne, initiate a gentle, barrier-conscious regimen (e.g., adapalene 0.1% gel 2–3 nights/week to affected areas with a non-comedogenic moisturizer; azelaic acid in the morning; benzoyl peroxide wash during inflamed flares), reassess at 8–12 weeks, and if inadequate, add an antiandrogen (e.g., spironolactone) while restricting any oral antibiotic use to a short bridge only.

This Newsletter Is Sponsored By Casa de Sante.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) — helps preserve lean muscle during weight loss
• FODMAP Digestive Enzymes — improves absorption and reduces GI side effects
• Advanced Probiotic + Prebiotic Synbiotic Formula — supports a balanced gut microbiome
• Essential Vitamin & Mineral Complex — replenishes nutrients often depleted during rapid weight loss
• Gentle Colon Cleanse + Probiotic Support — aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested, the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin, especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex — firms and smooths for youthful elasticity
• Antioxidant C+E Ferulic Radiance Serum — brightens and defends against oxidative stress
• Needle-Free Wrinkle Smoother — softens fine lines without irritation
• Ultra Retinol 10x + Bakuchiol Serum — boosts cell turnover with gentle plant retinol
• Advanced Retinol Eye Repair — targets puffiness and under-eye wrinkles
• Cellular Repair Growth Factor Peptides Serum — rejuvenates and supports skin repair
• Advanced Neck Lift Firming Complex — improves tone and texture along the jawline and neck
• Even Tone Brightening Cream — evens discoloration for radiant, balanced skin

Dr Onyx Adegbola MD PhD — Track Smarter. Eat Better. Thrive. Download the GLP1 Support App at https://casadesante.com/pages/app-glp-1-support-by-dr-onyx-md-phd